CD8A and COVID-19: Incorporating HLA-E-restricted CD8 T cells into T cell immunotherapy for COVID-19 offers several advantages, including the ability to eliminate infected cells, inhibit intracellular infection, reduce inflammatory reactions, and limit tissue damage, which are important mechanisms in the pathogenesis of COVID-19 [14].